|
|
||||||||
Journal of the American College of Nutrition, Vol 14, Issue 4 364-368, Copyright © 1995 by American College of Nutrition
CLINICAL TRIAL |
C. Serfaty-Lacrosniere, R. J. Wood, D. Voytko, J. R. Saltzman, M. Pedrosa, T. E. Sepe and R. R. Russell
Tufts University, Mineral Bioavailability Laboratory, USDA Human Nutrition Research Center on Aging, Boston, MA 02111, USA.
OBJECTIVE: Low gastric pH is generally believed to be an important factor in intestinal mineral absorption. Thus, hypochlorhydria could be an important risk factor for mineral malabsorption and the development of marginal mineral status. We studied whether the hypochlorhydria associated with treatment with the anti-ulcer medication omeprazole, a potent gastric proton pump inhibition, would affect intestinal calcium, phosphorus, magnesium, or zinc absorption from food. METHODS: Thirteen normal, healthy adults were assigned to either a control group (n = 5) receiving no drug treatment or an omeprazole treatment group (n = 8) to produce increased gastric pH. Omeprazole treatment of normal volunteers resulted in a significant change in postprandial gastric pH (pH 6.4 +/- 0.3 vs. 3.6 +/- 0.5 in control subjects, p < 0.01) and baseline fasting pH (pH 5.8 +/- 0.5 vs. pH 1.8 +/- 0.3 in controls, p < 0.01) after an overnight fast. Net mineral absorption from a standard test meal was measured using a whole gut lavage technique. Mineral absorption was measured twice in each subject, once with 120 mL of 0.1 mol/liter hydrochloric acid and a second time with 120 mL of distilled water alone. RESULTS: We found that despite marked changes in gastric pH due to drug treatment or administration of exogenous HCl, no change in the intestinal absorption of calcium, phosphorus, magnesium or zinc from a standard test meal was evident. CONCLUSIONS: These findings suggest that changing the gastric pH alone does not modify the net intestinal absorption of several minerals from food. Therefore, it is unlikely that moderate hypochlorhydria resulting from short-term omeprazole treatment substantially increases the risk for developing calcium, phosphorus, magnesium, or zinc deficiencies due to mineral malabsorption.
This article has been cited by other articles:
![]() |
N Shabajee, E J Lamb, I Sturgess, and R W Sumathipala Omeprazole and refractory hypomagnesaemia BMJ, July 10, 2008; 337(jul10_3): a425 - a425. [Full Text] |
||||
![]() |
Y.-X. Yang, J. D. Lewis, S. Epstein, and D. C. Metz Long-term Proton Pump Inhibitor Therapy and Risk of Hip Fracture JAMA, December 27, 2006; 296(24): 2947 - 2953. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. E. Kerstetter, K. O. O'Brien, D. M. Caseria, D. E. Wall, and K. L. Insogna The Impact of Dietary Protein on Calcium Absorption and Kinetic Measures of Bone Turnover in Women J. Clin. Endocrinol. Metab., January 1, 2005; 90(1): 26 - 31. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |